ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma Meeting Abstract
| Authors: | Makker, V.; Vergote, I.; Mirza, M.; Coleman, R.; Fidalgo, J. A. P.; Monk, B.; Valabrega, G.; Slomovitz, B.; van Gorp, T.; Moore, K.; Sehouli, J.; Cibula, D.; Levy, T.; Aravantinos, G.; Judson, P.; Rangwala, R.; Wang, X. |
| Abstract Title: | ENGOT-EN20/GOG-3083/XPORT-EC-042 A phase 3, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients (pts) with P53 wild-type, advanced or recurrent endometrial carcinoma |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women’s Cancer (54th Annual Meeting) |
| Journal Title: | Gynecologic Oncology |
| Volume: | 176 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Mar 25-28 |
| Meeting Location: | Tampa, FL |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2023-09-01 |
| Start Page: | S156 |
| Language: | English |
| ACCESSION: | WOS:001079556100244 |
| DOI: | 10.1016/j.ygyno.2023.06.155 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1246 -- Source: Wos |
